Last reviewed · How we verify

NCT07284693

Clinical Study Evaluating the Efficacy of Phenolic Complex k110-42 Therapy on Cognitive Functions of Children With Down Syndrome

Not yet recruiting Phase 3 Last updated 14 December 2025
What this trial tests

Phase 3 trial testing Phenolic complex k110-42 in Cognitive Functions in 108 participants. Not yet recruiting.

Timeline
1 January 2026
Primary endpoint
1 July 2026
1 December 2026

Quick facts

Lead sponsorMansoura University
PhasePhase 3
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment108
Start date1 January 2026
Primary completion1 July 2026
Estimated completion1 December 2026

Drugs / interventions tested

Conditions studied

Sponsor

Mansoura University

Who can join

Adults 4 to 8, any sex, with Cognitive Functions. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

The goal of this study is to evaluate the efficacy of phenolic complex k110-42 on cognitive function of children with Down syndrome

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cognitive Functions

Currently open trials in the same condition.

Other Mansoura University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07284693.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing